Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 16/20 | 0.70 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.41 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440160 | 1.00 | CHRM1 (0.70) | CHRM1KLKB1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL18756541 | 0.89 | CHRM1 (0.81) | CHRM1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL17440152 | 0.88 | CHRM1 (0.75) | CHRM1 | |
| SCHEMBL17440154 | 0.88 | CHRM1 (0.75) | CHRM1 | |
| SCHEMBL17440010 | 0.87 | CHRM1 (0.69) | CHRM1KLKB1 | |
| SCHEMBL17440008 | 0.87 | CHRM1 (0.69) | CHRM1KLKB1 | |
| SCHEMBL17440009 | 0.87 | CHRM1 (0.69) | CHRM1KLKB1 | |
| SCHEMBL17440113 | 0.87 | CHRM1 (0.78) | CHRM1 | |
| SCHEMBL17448018 | 0.84 | CHRM1 (0.67) | CHRM1 | |
| SCHEMBL17440118 | 0.84 | CHRM1 (0.68) | CHRM1KLKB1PRKAB2PRKAG1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885KLKB1 3991/4885PRKAB2 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.